Table 2. Univariate analysis on risk association of HPV58 E6 and E7 amino acid substitutions.
| Cervical pathology1 | ||||
|---|---|---|---|---|
|
|
||||
| Amino acid substitution | Normal (N = 79) | CIN3/ICC (N = 64) | p-value2 | Odds ratio (95% CI)3 |
| E6 | ||||
|
| ||||
| E25K | 0 | 1 | 0.448 | – |
|
| ||||
| E32Q | 3 | 0 | 0.253 | – |
|
| ||||
| V46I | 1 | 1 | 1.000 | 1.24 (0.00–46.34) |
|
| ||||
| V46T | 1 | 0 | 1.000 | – |
|
| ||||
| D86E | 4 | 1 | 0.380 | 0.30 (0.01–2.94) |
|
| ||||
| D86N | 1 | 0 | 1.000 | – |
|
| ||||
| K93N | 6 | 4 | 0.987 | 0.81 (0.18–3.45) |
|
| ||||
| C95R | 1 | 0 | 1.000 | – |
|
| ||||
| N97D | 1 | 1 | 1.000 | 1.24 (0.00–46.34) |
|
| ||||
| N97E | 1 | 0 | 1.000 | – |
|
| ||||
| E7 | ||||
|
| ||||
| R9K | 0 | 2 | 0.199 | – |
|
| ||||
| T20I | 15 | 27 | 0.004 | 3.11 (1.38–7.07) |
|
| ||||
| G41R | 46 | 25 | 0.035 | 0.46 (0.22–0.95) |
|
| ||||
| T50I | 1 | 0 | 1.000 | – |
|
| ||||
| G63D | 47 | 25 | 0.024 | 0.44 (0.21–0.90) |
|
| ||||
| G63H | 1 | 1 | 1.000 | 1.24 (0.00–46.34) |
|
| ||||
| G63S | 18 | 27 | 0.021 | 2.47 (1.13–5.44) |
|
| ||||
| T74A | 7 | 2 | 0.188 | 0.33 (0.05–1.84) |
|
| ||||
| D76E | 7 | 2 | 0.188 | 0.33 (0.05–1.84) |
|
| ||||
| V77A | 1 | 6 | 0.045 | 8.07 (0.92–182.76) |
1
Histology-confirmed CIN3 or invasive cervical cancer. Normal, no abnormalities detected by cytology or colposcopy or biopsy.
2
2 × 2 comparison between samples with and without the indicated amino acid substitution using χ2 test or Fisher's exact test. Significant associations are bolded.
3
–, odds ratio undefined; CI, confidence interval.